Pharma News

In a recent and impactful tweet, U.S. Senator Bernie Sanders (I-Vt.) has harshly criticized the pricing strategy of the highly-watched diabetes drug Ozempic and its manufacturer, Novo Nordisk A/S.

Charles River has implemented a series of investment strategies, including acquisitions, technology partnerships, and internal development, to gain access to innovative technologies and expertise.

BAY 2862789 oral solution, a small-molecule DGKα inhibitor co-developed by Bayer and the German Cancer Research Center (DKFZ), is now undergoing the first-in-human Phase 1 clinical trial globally.

SINOPEP's main source of revenue is its series of products, namely active pharmaceutical ingredients (APIs).

Batoclimab (HBM9161), as a fully human monoclonal antibody, works by blocking the interaction between FcRn and IgG, thereby accelerating the clearance of pathogenic IgG, providing an effective treatment for autoimmune diseases mediated by pathogenic IgG.

According to official documents released by the U.S. Securities and Exchange Commission (SEC), the pharmaceutical company Amylyx, headquartered in Cambridge, Massachusetts, successfully completed a transaction with Eiger last Friday.

The need to avoid future major illnesses is widespread, and the potential audience for cancer early screening theoretically covers almost the entire population.

On November 9, 2023, a historically significant day, fruquintinib was officially approved by the U.S. Food and Drug Administration (FDA), making it successfully available in the U.S. market.

This groundbreaking new indication approval is undoubtedly based on the excellent data from Merck's large-scale global Phase III clinical trial KEYNOTE-811.

On June 24, 2024, FORSUNPHARMA announced a major strategic move in its official announcement, planning to privatize its core innovative assets - Henlius - through an absorption and merger.

Semaglutide, the active ingredient in Novo Nordisk's Wegovy®, is a GLP-1 receptor agonist that works by binding to and activating the GLP-1 receptor, thereby exerting its effects in the treatment of obesity.

In the current healthcare landscape, the prevalence of pharmaceutical company advertising has become a focus of public concern.

In the current extreme climate environment, the hot and humid weather not only brings many inconveniences to people's daily lives, but also poses potential health risks to those who are taking medications.

In recent years, with growing public interest in health and weight management, the market acceptance of new weight loss drugs such as Ozempic, Wegovy, and Mounjaro has been steadily increasing.

In recent years, the treatment of primary biliary cholangitis (PBC) has seen remarkable progress, with the continuous introduction of new drugs bringing good news to PBC patients worldwide.

Recently, the U.S. Food and Drug Administration (FDA) published an important update on its official website, announcing the implementation of automatic detention on herbal medicine and Yuquan pill products exported by a Chinese company.

In the tumultuous world of the pharmaceutical industry, the Swiss pharmaceutical giant Roche has once again demonstrated its firm steps in acquisitions and expansions.

Jichuan Pharmaceutical, a pharmaceutical company that has been deeply engaged in the field of children's medicines for many years, has recently announced its impressive first-quarter financial results for 2024.

In recent years, as people's living standards have improved and dietary structures have changed, the problems of overweight and obesity have become increasingly prominent, becoming an important public health issue globally.

MustangBio, a leading U.S. biotech company, has recently achieved a remarkable breakthrough.